Breaking News: NewAmsterdam Pharma Launches $300 Million Public Offering for Ordinary Shares and Pre-Funded Warrants!
Naarden, The Netherlands and Miami, Dec. 10, 2024 (GLOBE NEWSWIRE)
NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease (“CVD”) with elevated low-density lipoprotein cholesterol (“LDL-C”), for whom existing therapies are not sufficiently effective or well-tolerated, today announced the commencement of an underwritten public offering of $300.0 million of the Company’s ordinary shares, nominal value €0.12 per share (the “Ordinary Shares”), and, to certain investors that so choose in lieu of Ordinary Shares, pre-funded warrants to purchase Ordinary Shares (“Pre-Funded Warrants,” and such offering, the “Offering”). All Ordinary Shares and Pre-Funded Warrants to be sold in the proposed Offering will be sold by the Company. In addition, the Company expects to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of Ordinary Shares, less underwriting discounts and commissions. The proposed Offering is subject to market and other conditions and there can be no assurance as to whether or when the proposed Offering may be completed, or as to the actual size or terms of the proposed Offering.
Effect on Me:
As a potential investor, this news could present an opportunity to invest in a growing biopharmaceutical company focused on developing innovative medicines for patients with cardiovascular disease. By participating in the public offering, you could have a stake in the future success of NewAmsterdam Pharma and potentially see a return on your investment if the company continues to thrive in the market.
Effect on the World:
The launch of a $300 million public offering by NewAmsterdam Pharma signifies a significant development in the biopharmaceutical industry. This funding will allow the company to further its research and development efforts in creating new non-statin medicines for patients at risk of cardiovascular disease. If successful, these medicines could potentially help improve outcomes for individuals with elevated LDL-C levels who have not responded well to existing treatments, ultimately making a positive impact on global healthcare.
Conclusion:
In conclusion, the public offering by NewAmsterdam Pharma represents a pivotal moment in the company’s growth trajectory and the potential advancement of cardiovascular disease treatment options. As investors consider participating in this offering, they have the opportunity to support innovative research and potentially benefit from the success of a company dedicated to improving patient outcomes in the field of CVD.
